Probiotics in COPD: Effects on Symptoms, Lung Function, and Inflammation (NCT07339280) | Clinical Trial Compass
By InvitationNot Applicable
Probiotics in COPD: Effects on Symptoms, Lung Function, and Inflammation
Croatia60 participantsStarted 2026-03-08
Plain-language summary
The goal of this randomized, placebo controlled, double-blind clinical trial is to find out whether a probiotic supplement can help adults with chronic obstructive pulmonary disease (COPD) breathe better and better control their symptoms. The study will try to answer does taking a probiotic supplement, compare with a placebo, reduce shortness of breath, does it improve daily COPD symptoms or change stool patterns by using validated questionnaires; does it affect lung function or inflammation. The results of this study may contribute to a better understanding of the disease, the application of new therapeutic options, and provide a foundation for future research.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patients with a previously established diagnosis of COPD, regardless of the degree of airflow obstruction on pulmonary function testing.
✓. Age over 18 years, regardless of sex.
✓. Stable disease without exacerbations during the past two months (8 weeks).
✓. Stable disease without changes to maintenance therapy during the past two months (8 weeks).
✓. Patients with an mMRC score of 1 or higher.
✓. Signed informed consent.
Exclusion criteria
✕. patients diagnosed with serious comorbidities such as severe cardiovascular diseases (severe heart failure, acute coronary syndrome, or percutaneous coronary intervention within 6 months, uncontrolled tachy/bradyarrhythmias), patients with severe renal failure and a placed central venous catheter, patients with severe liver damage (Child-Pugh class C), patients with infectious hepatitis or HIV, active bloody diarrhea;
✕. patients undergoing active oncological and hematological treatment;
. patients who have had a stroke within the past 3 months;
✕. transplanted patients, including allograft recipients;
✕. patients on long-term systemic corticosteroid and immunosuppressive therapy (oral or intravenous form) as well as antifungal therapy,
✕. patients who have had a COPD exacerbation within the past two months and are not in a stable condition,
✕. patients diagnosed with asthma,
✕. patients with a history of lung surgery or serious respiratory diseases other than COPD (active tuberculosis, sarcoidosis, pulmonary fibrosis, severe bronchiectasis, pulmonary aspergillosis, etc.),